全文获取类型
收费全文 | 1016190篇 |
免费 | 71877篇 |
国内免费 | 1701篇 |
专业分类
耳鼻咽喉 | 14560篇 |
儿科学 | 26970篇 |
妇产科学 | 25286篇 |
基础医学 | 143888篇 |
口腔科学 | 31863篇 |
临床医学 | 86504篇 |
内科学 | 203918篇 |
皮肤病学 | 21877篇 |
神经病学 | 78949篇 |
特种医学 | 38595篇 |
外国民族医学 | 80篇 |
外科学 | 162238篇 |
综合类 | 18588篇 |
现状与发展 | 1篇 |
一般理论 | 263篇 |
预防医学 | 70869篇 |
眼科学 | 22842篇 |
药学 | 78566篇 |
3篇 | |
中国医学 | 2705篇 |
肿瘤学 | 61203篇 |
出版年
2021年 | 8576篇 |
2019年 | 8594篇 |
2018年 | 12277篇 |
2017年 | 9010篇 |
2016年 | 9713篇 |
2015年 | 11097篇 |
2014年 | 15148篇 |
2013年 | 21816篇 |
2012年 | 30476篇 |
2011年 | 31895篇 |
2010年 | 18477篇 |
2009年 | 17261篇 |
2008年 | 29578篇 |
2007年 | 30870篇 |
2006年 | 31220篇 |
2005年 | 30136篇 |
2004年 | 28781篇 |
2003年 | 27525篇 |
2002年 | 26699篇 |
2001年 | 56483篇 |
2000年 | 58459篇 |
1999年 | 48519篇 |
1998年 | 11234篇 |
1997年 | 9883篇 |
1996年 | 9908篇 |
1995年 | 9225篇 |
1994年 | 8524篇 |
1993年 | 7787篇 |
1992年 | 36150篇 |
1991年 | 34432篇 |
1990年 | 33215篇 |
1989年 | 32256篇 |
1988年 | 29359篇 |
1987年 | 28586篇 |
1986年 | 26591篇 |
1985年 | 25418篇 |
1984年 | 18018篇 |
1983年 | 15322篇 |
1982年 | 7923篇 |
1979年 | 15938篇 |
1978年 | 10720篇 |
1977年 | 9120篇 |
1976年 | 7948篇 |
1975年 | 8713篇 |
1974年 | 10616篇 |
1973年 | 9959篇 |
1972年 | 9447篇 |
1971年 | 8969篇 |
1970年 | 8526篇 |
1969年 | 8035篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
T. Wu L. G. Trahair M. J. Bound C. F. Deacon M. Horowitz C. K. Rayner K. L. Jones 《Diabetic medicine》2015,32(5):595-600
62.
63.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
64.
65.
66.
67.
Focal hyperhidrosis secondary to eccrine naevus successfully treated with botulinum toxin type A
下载免费PDF全文
![点击此处可从《Clinical and experimental dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Eccrine naevus (EN) is a rare skin hamartoma included in the organoid group of epidermal naevi, histologically defined as focal hyperplasia and/or hypertrophy of eccrine glands. Clinically, EN usually presents as hyperhidrotic patches with no visible skin changes, frequently located on the forearms. The decision to treat EN or not usually depends on the grade of hyperhidrosis, but there is no therapeutic consensus because of the rarity of this condition. We present a case diagnosed as EN in an adult patient with severe localized hyperhidrosis, which was successfully treated with botulinum toxin. 相似文献
68.
Enrique Luengo Izaskun Buendia Cristina Fernndez‐Mendívil Paula Trigo‐Alonso Pilar Negredo Patrycja Michalska Borja Hernndez‐García Cristina Snchez‐Ramos Juan A. Bernal Tsuneya Ikezu Rafael Len Manuela G. Lpez 《Journal of pineal research》2019,67(1)
Alterations in autophagy are increasingly being recognized in the pathogenesis of proteinopathies like Alzheimer's disease (AD). This study was conducted to evaluate whether melatonin treatment could provide beneficial effects in an Alzheimer model related to tauopathy by improving the autophagic flux and, thereby, prevent cognitive decline. The injection of AAV‐hTauP301L viral vectors and treatment/injection with okadaic acid were used to achieve mouse and human ex vivo, and in vivo tau‐related models. Melatonin (10 μmol/L) impeded oxidative stress, tau hyperphosphorylation, and cell death by restoring autophagy flux in the ex vivo models. In the in vivo studies, intracerebroventricular injection of AAV‐hTauP301L increased oxidative stress, neuroinflammation, and tau hyperphosphorylation in the hippocampus 7 days after the injection, without inducing cognitive impairment; however, when animals were maintained for 28 days, cognitive decline was apparent. Interestingly, late melatonin treatment (10 mg/kg), starting once the alterations mentioned above were established (from day 7 to day 28), reduced oxidative stress, neuroinflammation, tau hyperphosphorylation, and caspase‐3 activation; these observations correlated with restoration of the autophagy flux and memory improvement. This study highlights the importance of autophagic dysregulation in tauopathy and how administration of pharmacological doses of melatonin, once tauopathy is initiated, can restore the autophagy flux, reduce proteinopathy, and prevent cognitive decline. We therefore propose exogenous melatonin supplementation or the development of melatonin derivatives to improve autophagy flux for the treatment of proteinopathies like AD. 相似文献
69.
70.